Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Related Videos

Related Content

Advertisement

May 7th 2025

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

Jared Kaltwasser

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

May 6th 2025

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

Hayden E. Klein

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

May 5th 2025

Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR

Mary Caffrey

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).

May 3rd 2025

From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

Mary Caffrey

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A phase 3 trial is on track to release results this fall.

Related Content

Advertisement

May 7th 2025

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

Jared Kaltwasser

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

May 6th 2025

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

Hayden E. Klein

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

May 5th 2025

Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR

Mary Caffrey

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).

May 3rd 2025

From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

Mary Caffrey

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A phase 3 trial is on track to release results this fall.